Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting

被引:3
|
作者
Konishi, Keiji [1 ,2 ,3 ]
Onozuka, Daisuke [2 ,3 ]
Okubo, Moeka [4 ]
Kasamatsu, Yu [1 ]
Kutsuna, Satoshi [2 ,3 ]
Shirano, Michinori [1 ]
机构
[1] Osaka City Gen Hosp, Dept Infect Dis, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Postinfect Dis Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[3] Osaka Univ, Grad Sch Med, Dept Infect Control & Prevent, Osaka, Japan
[4] Osaka City Gen Hosp, Dept Pharm, Osaka, Japan
关键词
Antiretroviral therapy; Long-acting antiretroviral therapy; Adherence; Cabotegravir; Rilpivirine; Japanese; TENOFOVIR DISOPROXIL FUMARATE; CABOTEGRAVIR PLUS RILPIVIRINE; HIV-1; INFECTION; OPEN-LABEL; RESISTANT HIV-1; PHASE-3; ADULTS; ALAFENAMIDE; EFFICACY; SAFETY;
D O I
10.1186/s12879-024-09904-x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background Antiretroviral therapy (ART) for HIV infection has evolved substantially. The development of long-acting drugs, such as cabotegravir (CAB) and rilpivirine (RPV) might improve treatment satisfaction among people living with HIV (PLWH). The real-world effectiveness of long-acting ART and its effect on patient satisfaction needs to be assessed. This study investigated antiviral effectiveness and treatment satisfaction in PLWH who switched from conventional to long-acting ART (CAB + RPV). Methods This prospective cohort study included PLWH aged 18 years and older who switched to CAB + RPV and received the injections every 8 weeks between June 2022 and May 2023, after a 4-week oral lead-in phase. The eligibility criteria included viral suppression, absence of hepatitis B virus (HBV) DNA, and no prior RPV resistance mutations. Clinical data, including renal, lipid, and glucose biomarker levels, were monitored from the baseline to 44 weeks after switching. Treatment satisfaction was assessed using the HIV Treatment Satisfaction Questionnaire. A linear mixed-effects model was used to estimate changes in clinical data from baseline. Results Thirty-eight male participants were enrolled. Some participants had detectable levels of viral replication; however, all participants maintained viral suppression (HIV-RNA < 50 copies/mL) at 44 weeks and no cases of virological failure were detected. The creatinine level decreased by - 0.04 mg/dL (95% confidence interval [CI]: - 0.07 to - 0.01), lipid and glucose profiles remained stable, and treatment satisfaction increased by 6.6 points (95% CI: 2.4 to 10.8) after switching to CAB + RPV. Conclusions Long-acting ART provides effective viral suppression and enhances treatment satisfaction in PLWH switching from conventional ART. Long-acting ART can improve patient well-being; however, patient selection and monitoring to prevent HBV-related complications are important.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Development of conceptual models to understand patient experiences with and attributes of adherence to HIV oral antiretroviral therapy and considerations in switching to long-acting oral antiretroviral therapy
    Bailey, J.
    Javidnia, P.
    Mao, J.
    Borsa, A.
    Hawryluk, E.
    Gubernick, S.
    de la Motte, A.
    Fonseca, E.
    Karantzoulis, S.
    Reaney, M.
    Saretsky, T.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 42 - 43
  • [42] SCHIZOPHRENIA PATIENT PERSISTENCE TO LONG-ACTING ANTIPSYCHOTIC THERAPY IN NEW ZEALAND
    Berney, K.
    Grant, A.
    Acar, M.
    Shaw, S.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 139 - 139
  • [43] Real-World Effectiveness of Secukinumab in the Treatment of Ankylosing Spondylitis in Canada: Retrospective Analysis Using Data from the Patient Support Program
    Aydin, Sibel
    Rahman, Proton
    Chan, Jonathan
    Wang, Ching-An
    Chen, Yen-Hua
    Tian, Haijun
    Leclerc, Patrick
    Parent, Sophie
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1040 - 1040
  • [44] LONG-ACTING INJECTABLE ANTIPSYCHOTICS: FROM PHARMACOKINETICS TO THE BENEFITS FOR THE PATIENT
    Fraguas, D.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 5 - 6
  • [45] PATIENT PREFERENCES FOR LONG-ACTING ANTIRETROVIRAL THERAPY AMONG PATIENTS LIVING WITH HIV IN KENYA: RESULTS FROM A PILOT DISCRETE CHOICE EXPERIMENT
    Tran, J.
    Barthold, D.
    Hauber, B.
    Kaggiah, A.
    Maina, C.
    Kinuthia, J.
    Simoni, J. M.
    Graham, S. M.
    VALUE IN HEALTH, 2023, 26 (06) : S351 - S351
  • [46] Use of Long-Acting Muscarinic Antagonists and Biologic Therapy as Add-On Treatment for Asthma: Real-World Data Analysis Using Insurance Claims from 2012-2017
    Chen, H.
    Ding, Y.
    Spain, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [47] Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey
    Keenan, Alexander
    Lin, Dee
    Shepherd, Jason
    Bailey, Hollie
    Benson, Carmela
    Meakin, Sophie
    BMC PSYCHIATRY, 2022, 22 (01)
  • [48] Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy
    Bengtson, Lindsay G. S.
    DePietro, Michael
    McPheeters, Jeffrey
    Fox, Kathleen M.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
  • [49] Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey
    Alexander Keenan
    Dee Lin
    Jason Shepherd
    Hollie Bailey
    Carmela Benson
    Sophie Meakin
    BMC Psychiatry, 22
  • [50] Patient satisfaction after switching from a monthly to a quarterly administered long-acting injectables: A case series
    Pardo de Santayana, G.
    EUROPEAN PSYCHIATRY, 2018, 48 : S504 - S504